Clozapine Use in Children and Adolescents

Overview

Clozapine remains the sole antipsychotic with demonstrated superiority in treatment-resistant schizophrenia (TRS), yet its application in pediatric and adolescent populations is reported as infrequent globally and within Croatia. Prescribing delays frequently occur despite accumulating efficacy evidence, attributed to concerns regarding adverse effects and requirements for intensive monitoring. The review addresses this clinical gap by synthesizing available evidence on clozapine's efficacy and safety profile in pediatric populations, including pharmacological mechanisms, therapeutic potential, and adverse effects. A case presentation of an adolescent with disorganized treatment-resistant schizophrenia is presented, demonstrating clinical improvement following clozapine implementation in combination with adjunctive pharmacotherapy.

Methods and approach

This review examined available literature on clozapine efficacy and safety in pediatric populations. The analysis incorporated pharmacological mechanisms of action, therapeutic applications, and adverse effect profiles relevant to child and adolescent psychiatric practice. Clinical data were synthesized from published evidence supplemented by a case study of an adolescent with treatment-resistant disorganized schizophrenia managed with clozapine and additional pharmacological agents.

Results

The analysis confirms clozapine's superior efficacy in treatment-resistant schizophrenia across pediatric and adolescent cohorts where other antipsychotics have demonstrated inadequate clinical response. The case presentation illustrates clinical improvement in a treatment-resistant presentation following clozapine initiation with concurrent pharmacological support. However, the review documents substantial underutilization of clozapine in child and adolescent psychiatric settings despite evidence of efficacy, reflecting persistent gaps between research evidence and clinical practice implementation.

Implications

The findings underscore a significant clinical gap between documented clozapine efficacy and its limited application in pediatric and adolescent populations. Prescribing delays stem from legitimate safety monitoring requirements, yet the evidence base supports timely introduction in appropriate treatment-resistant cases. Establishment of evidence-based clinical guidelines and increased dissemination of efficacy and safety data within pediatric psychiatric literature may facilitate earlier and more appropriate clozapine implementation. The documented underutilization in both international and Croatian clinical contexts suggests need for educational initiatives targeting clinicians regarding risk-benefit assessment and monitoring protocols. Enhanced availability of peer-reviewed case reports and clinical guidance specific to pediatric populations may reduce barriers to appropriate clozapine use in treatment-resistant presentations.